Immune-checkpoint inhibitors in hematologic malignancies

DOI Web Site PubMed
  • MARUYAMA Dai
    Department of Hematology, National Cancer Center Hospital

Bibliographic Information

Other Title
  • 造血器悪性腫瘍に対する免疫チェックポイント阻害薬
  • ゾウケツキ アクセイ シュヨウ ニ タイスル メンエキ チェックポイント ソガイヤク

Search this article

Abstract

<p>Immuno-checkpoint inhibitors are one of the most promising immunotherapies for various advanced cancers including hematologic malignancies. Recently, enhanced signaling of the PD-1/CTLA4 pathway has emerged as a critical mechanism by which tumors can escape the anti-tumor immune response. PD-1-blocking antibodies have been used to enhance immunity in several malignancies and obtain durable responses, especially in patients with heavily treated relapsed/refractory Hodgkin lymphoma. Currently, several clinical trials including single agent or combination therapies for hematologic malignancies, such as Hodgkin lymphoma, B-cell lymphomas and multiple myeloma, are ongoing. The results of ongoing and future clinical trials may establish a new treatment paradigm for hematologic malignancies.</p>

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 57 (11), 2381-2387, 2016

    The Japanese Society of Hematology

Keywords

Details 詳細情報について

Report a problem

Back to top